Disialoganglioside directed immunotherapy of neuroblastoma Journal Article
| Authors: | Modak, S.; Cheung, N. K. V. |
| Article Title: | Disialoganglioside directed immunotherapy of neuroblastoma |
| Abstract: | Achieving a cure for metastatic neuroblastoma remains a challenge despite sensitivity to chemotherapy and radiotherapy. Most patients achieve remission, but a failure to eliminate minimal residual disease (MRD) often leads to relapse. Immunotherapy is potentially useful for chemotherapy-resistant disease and may be particularly effective for low levels of MRD that are below the threshold for detection by routine radiological and histological methods. Disialoganglioside (GD2), a surface glycolipid antigen that is ubiquitous and abundant on neuroblastoma cells is an ideal target for immunotherapy. Anti-GD2 monoclonal antibodies currently form the mainstay of neuroblastoma immunotherapy and their safety profile has been well-established. Although responses in patients with gross disease have been observed infrequently, histologic responses of bone marrow disease are consistently achieved in >75 percent of patients with primary refractory neuroblastoma. The advent of highly sensitive and specific molecular assays to measure MRD has confirmed the efficacy anti-GD2 antibody immunotherapy in patients with subclinical disease. Such markers will allow further optimization of other anti-MRD therapies. We review the current status of anti-GD2 clinical trials for neuroblastoma and novel preclinical GD2-targeted strategies for this rare but often lethal childhood cancer. Copyright © Informa Healthcare. |
| Keywords: | child; unclassified drug; clinical trial; disease course; review; doxorubicin; diarrhea; drug efficacy; drug safety; hypertension; nonhuman; side effect; antineoplastic agents; drug targeting; adjuvant therapy; animals; bcg vaccine; interleukin 2; cancer immunotherapy; melanoma; multiple cycle treatment; pain; bone marrow suppression; vomiting; granulocyte macrophage colony stimulating factor; continuous infusion; childhood cancer; cancer resistance; monoclonal antibody; chill; coughing; drug dose escalation; drug fever; rash; drug induced headache; membrane antigen; antibodies, monoclonal; immunotherapy; add on therapy; neuroblastoma; minimal residual disease; neoplasm, residual; cancer immunization; radiopharmaceutical agent; single drug dose; injection site pain; blood pressure; hypothyroidism; beta glucan; tumor vaccine; radioimmunotherapy; neuropathic pain; clinical trials; tachycardia; immunoliposome; urticaria; monoclonal antibody 3f8; monoclonal antibody 3f8 i 131; bone marrow disease; monoclonal antibody 3f8 i 124; qs 21; gangliosides; fenretinide; gd2; idiotypic antibody; passive immunization; antisense oligodeoxynucleotide; mydriasis; ophthalmoplegia; calicheamicin; disialoganglioside 2; disialoganglioside 2 antibody; disialoganglioside 2 lactone klh vaccine; granulocyte macrophage colony stimulating factor interleukin 2 fusion protein; monoclonal antibody 14g2a; monoclonal antibody 14g2a i 131; monoclonal antibody 1a7; monoclonal antibody ch14.18; monoclonal antibody ch14.18 tc 99m; monoclonal antibody hu14.18 interleukin fusion protein; monoclonl antibody a1g4; ricin |
| Journal Title: | Cancer Investigation |
| Volume: | 25 |
| Issue: | 1 |
| ISSN: | 0735-7907 |
| Publisher: | Informa Healthcare |
| Date Published: | 2007-02-01 |
| Start Page: | 67 |
| End Page: | 77 |
| Language: | English |
| DOI: | 10.1080/07357900601130763 |
| PUBMED: | 17364560 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 33" - "Export Date: 17 November 2011" - "CODEN: CINVD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work